collage of highlighted papers

Highlighted papers

2025

Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection
Duff, E.P., Zetterberg, H., Heslegrave, A. et al. Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection. Nat Med 31, 797–806 (2025)

Nature Medicine
Published 30 January 2025
Centre Members: Prof Paul Matthews & Dr Eugene Duff
Download paper

Previous studies have suggested that systemic viral infections may increase risks of dementia. To determine whether this holds true for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, we measured plasma biomarkers linked to Alzheimer’s disease pathology in the UK Biobank before and after serology-confirmed SARS-CoV-2 infections. SARS-CoV-2 infection was associated with biomarkers associated with β-amyloid pathology: reduced plasma Aβ42:Aβ40 ratio and, in more vulnerable participants, lower plasma Aβ42 and higher plasma pTau-181. The plasma biomarker changes were greater in participants who had been hospitalized with COVID-19 or had reported hypertension previously. We showed that the changes in biomarkers were linked to brain structural imaging patterns associated with Alzheimer’s disease, lower cognitive test scores and poorer overall health evaluations. Our data from this post hoc case–control matched study thus provide observational biomarker evidence that SARS-CoV-2 infection can be associated with greater brain β-amyloid pathology in older adults.

UK DRI